Cytokine production by macrophages in association with phagocytosis of etoposide-treated P388 cells in vitro and in vivo.
Chemotherapy and radiotherapy are performed for cancer patients with the hope that dying cancer cells are safely scavenged by phagocytic cells such as macrophages. In this study, we examined cytokine production by macrophages during and after the phagocytosis of etoposide-treated P388 cells in vitro and in vivo. Etoposide caused apoptosis as early as 5 h after treatment, as assessed as to the exposure of phosphatidylserine, increase in membrane permeability and DNA ladder formation. Phagocytosis by phorbol myristate acetate (PMA)-treated THP-1 cells occurred marginally when P388 cells were treated with etoposide for 10 h, while it occurred significantly with P388 cells treated for 24 h, as evidenced by flow cytometry and confocal microscopy. PMA-treated THP-1 cells produced pro-inflammatory cytokines, such as interleukin (IL)-1alpha, IL-8 and macrophage migration inhibitory factor (MIF), but not anti-inflammatory cytokines among those tested at the mRNA level during and after the phagocytosis of apoptotic cells. IL-8 and MIF were also produced at the protein level, and the IL-8 production was dependent on cell-to-cell contact when the plasma membranes of apoptotic cells were intact enough not to leak one of the cytoplasmic enzymes, lactate dehydrogenase. In addition, etoposide-treated P388 cells induced neutrophil infiltration as well as MIP-2 production upon injection into the peritoneal cavity of either normal mice or mice with sterile peritonitis. When macrophages ingesting and/or binding apoptotic P388 cells were isolated from the mice with sterile peritonitis using a cell sorter, they were found to produce MIP-2 upon culture.
Kawagishi
C
C
Department of Biomolecular Science, Faculty of Science, Toho University, 2-2-1 Miyama, Chiba 274-8510, Funabashi, Japan.
Kurosaka
K
K
Watanabe
N
N
Kobayashi
Y
Y
D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D017209:Apoptosis; D054426:Chemokine CXCL2; D018925:Chemokines / Q000032:analysis; D018920:Coculture Techniques; D016207:Cytokines / Q000032:analysis / Q000096:biosynthesis*; D005047:Etoposide / Q000494:pharmacology* / Q000627:therapeutic use; D005434:Flow Cytometry; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis; D007941:Leukemia P388 / Q000188:drug therapy* / Q000276:immunology; D008264:Macrophages / Q000378:metabolism*; D008297:Male; D051379:Mice; D018613:Microscopy, Confocal; D009368:Neoplasm Transplantation; D009842:Oligopeptides / Q000494:pharmacology; D010587:Phagocytosis; D013755:Tetradecanoylphorbol Acetate; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000972:Antineoplastic Agents, Phytogenic; D054426:Chemokine CXCL2; D018925:Chemokines; C404915:Cxcl2 protein, mouse; D016207:Cytokines; D016209:Interleukin-8; D009842:Oligopeptides; D005047:Etoposide; C059453:RGES peptide; C046617:arginyl-glycyl-aspartyl-serine; D013755:Tetradecanoylphorbol Acetate